Zarcone V P, Berger P A, Brodie K H, Sack R, Barchas J D
Dis Nerv Syst. 1977 Aug;38(8):646-53.
This paper reviews the evidence for a specific indoleamine deficiency in depression and the attempts to correct this suspected deficiency with serotonin precursors. It also presents the clinical and biochemical data on six patients with depression treated with L-5-HTP in a nonrandom, double-blind protocol. The oral administration of L5-HTP was associated with a rise in CSF5-HIAA, but only two of six patients studied had any decrease in depression ratings. 5-HTP was also shown to decrease urinary excretion of 17 hydroxycorticosteroids in twodepressed patients and three normal controls suggesting an interrelationship between serotonin metabolism and the pituitary adrenal system. This leads to the suggestion that in a postulated subgroup of depressed patients with pituitary adrenal hyperactivity and evidence of serotonin deficiency, L5-HTP deserves a further trial as an experimental treatment.
本文综述了抑郁症中特定吲哚胺缺乏的证据，以及用血清素前体纠正这种疑似缺乏的尝试。它还展示了在一项非随机、双盲方案中用L-5-羟色氨酸治疗的6例抑郁症患者的临床和生化数据。口服L-5-羟色氨酸与脑脊液5-羟吲哚乙酸升高有关，但在研究的6例患者中只有2例抑郁评分有所降低。5-羟色氨酸还被证明可降低2例抑郁症患者和3例正常对照者的17-羟皮质类固醇尿排泄量，提示血清素代谢与垂体-肾上腺系统之间存在相互关系。这表明，在假定的垂体-肾上腺功能亢进且有血清素缺乏证据的抑郁症亚组患者中，L-5-羟色氨酸作为一种实验性治疗值得进一步试验。
